{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T20:27:32Z","timestamp":1790195252045,"version":"4.1.0"},"reference-count":31,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>COVID-19 pneumonia is often associated with hyperinflammation. The efficacy and safety of anakinra in treating patients with severe COVID-19 pneumonia and hyperinflammation are still unclear.<\/jats:p><\/jats:sec>Objective<\/jats:title>To assess the efficacy and safety of anakinra vs standard of care alone for patients with severe COVID-19 pneumonia and hyperinflammation.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>The Clinical Trial of the Use of Anakinra in Cytokine Storm Syndrome Secondary to COVID-19 (ANA-COVID-GEAS) was a multicenter, randomized, open-label, 2-group, phase 2\/3 clinical trial conducted at 12 hospitals in Spain between May 8, 2020, and March 1, 2021, with a follow-up of 1 month. Participants were adult patients with severe COVID-19 pneumonia and hyperinflammation. Hyperinflammation was defined as interleukin-6\u2009greater than\u200940 pg\/mL, ferritin greater than 500 ng\/mL, C-reactive protein greater than 3 mg\/dL (rationale, \u22655 upper normal limit), and\/or lactate dehydrogenase greater than 300 U\/L. Severe pneumonia was considered if at least 1 of the following conditions was met: ambient air oxygen saturation 94% or less measured with a pulse oximeter, ratio of partial pressure O2<\/jats:sub> to fraction of inspired O2<\/jats:sub> of 300 or less, and\/or a ratio of O2<\/jats:sub> saturation measured with pulse oximeter to fraction of inspired O2<\/jats:sub> of 350 or less. Data analysis was performed from April to October 2021.<\/jats:p><\/jats:sec>Interventions<\/jats:title>Usual standard of care plus anakinra (anakinra group) or usual standard of care alone (SoC group). Anakinra was given at a dose of 100 mg 4 times a day intravenously.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The primary outcome was the proportion of patients not requiring mechanical ventilation up to 15 days after treatment initiation, assessed on an intention-to-treat basis.<\/jats:p><\/jats:sec>Results<\/jats:title>A total of 179 patients (123 men [69.9%]; mean [SD] age, 60.5 [11.5] years) were randomly assigned to the anakinra group (92 patients) or to the SoC group (87 patients). The proportion of patients not requiring mechanical ventilation up to day 15 was not significantly different between groups (64 of 83 patients [77.1%] in the anakinra group vs 67 of 78 patients [85.9%] in the SoC group; risk ratio [RR], 0.90; 95% CI, 0.77-1.04; P<\/jats:italic>\u2009=\u2009.16). Anakinra did not result in any difference in time to mechanical ventilation (hazard ratio, 1.72; 95% CI, 0.82-3.62; P<\/jats:italic>\u2009=\u2009.14). There was no significant difference between groups in the proportion of patients not requiring invasive mechanical ventilation up to day 15 (RR, 0.99; 95% CI, 0.88-1.11; P<\/jats:italic>\u2009&amp;gt;\u2009.99).<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this randomized clinical trial, anakinra did not prevent the need for mechanical ventilation or reduce mortality risk compared with standard of care alone among hospitalized patients with severe COVID-19 pneumonia.<\/jats:p><\/jats:sec>Trial Registration<\/jats:title>ClinicalTrials.gov Identifier: NCT04443881<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2023.7243","type":"journal-article","created":{"date-parts":[[2023,4,7]],"date-time":"2023-04-07T15:02:04Z","timestamp":1680879724000},"page":"e237243","source":"Crossref","is-referenced-by-count":26,"title":["Efficacy and Safety of Anakinra Plus Standard of Care for Patients With Severe COVID-19"],"prefix":"10.1001","volume":"6","author":[{"given":"Patricia","family":"Fanlo","sequence":"first","affiliation":[{"name":"Unidad de Enfermedades Autoinmunes Sist\u00e9micas, Servicio de Medicina Interna, Hospital Universitario de Navarra, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borja del Carmelo","family":"Gracia-Tello","sequence":"additional","affiliation":[{"name":"Unidad de Enfermedades Autoinmunes Sist\u00e9micas, Servicio de Medicina Interna, Hospital Universitario Cl\u00ednico Lozano Blesa, Zaragoza, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Fonseca Aizpuru","sequence":"additional","affiliation":[{"name":"Unidad de Enfermedades Autoinmunes Sist\u00e9micas, Servicio de Medicina Interna, Hospital de Cabue\u00f1es, Gij\u00f3n, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"\u00c1lvarez-Troncoso","sequence":"additional","affiliation":[{"name":"Unidad de Enfermedades Autoinmunes Sist\u00e9micas, Servicio de Medicina Interna, Hospital La Paz, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s","family":"Gonzalez","sequence":"additional","affiliation":[{"name":"Unidad de Enfermedades Autoinmunes Sist\u00e9micas, Servicio de Medicina Interna, Hospital Ram\u00f3n y Cajal, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Prieto-Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"Servicio de Enfermedades Autoinmunes Sist\u00e9micas, Hospital Clinic, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayka","family":"Freire","sequence":"additional","affiliation":[{"name":"Unidad de Enfermedades Autoinmunes Sist\u00e9micas, Servicio de Medicina Interna, Complejo Hospitalario de Santiago, Santiago de Compostela, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Bel\u00e9n","family":"Argibay","sequence":"additional","affiliation":[{"name":"Unidad de Enfermedades Autoinmunes Sist\u00e9micas, Servicio de Medicina Interna, Complejo Hospitalario de Vigo, Vigo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucio","family":"Pallar\u00e9s","sequence":"additional","affiliation":[{"name":"Unidad de Enfermedades Autoinmunes Sist\u00e9micas, Servicio de Medicina Interna, Hospital Son Espases, Palma de Mallorca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Antonio","family":"Todol\u00ed","sequence":"additional","affiliation":[{"name":"Unidad de Enfermedades Autoinmunes Sist\u00e9micas, Servicio de Medicina Interna, Hospital Universitario La Fe, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercedes","family":"P\u00e9rez","sequence":"additional","affiliation":[{"name":"Unidad de Enfermedades Autoinmunes Sist\u00e9micas, Servicio de Medicina Interna, Hospital Universitario Miguel Servet, Zaragoza, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Segundo","family":"Buj\u00e1n-Rivas","sequence":"additional","affiliation":[{"name":"Unidad de Enfermedades Autoinmunes Sist\u00e9micas, Servicio de Medicina Interna, Hospital Vall d\u00b4Hebron, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berta","family":"Ib\u00e1\u00f1ez","sequence":"additional","affiliation":[{"name":"Navarrabiomed, Hospital Universitario de Navarra, Universidad P\u00fablica de Navarra, Red de Investigaci\u00f3n en Cronicidad, Atenci\u00f3n Primaria y Prevenci\u00f3n y Promoci\u00f3n de la Salud, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"GEAS-SEMI Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rub\u00e9n","family":"Arn\u00e1ez","sequence":"additional","affiliation":[{"name":"for the GEAS-SEMI Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Huarte","sequence":"additional","affiliation":[{"name":"for the GEAS-SEMI Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Sanchez","sequence":"additional","affiliation":[{"name":"for the GEAS-SEMI Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Zabalza","sequence":"additional","affiliation":[{"name":"for the GEAS-SEMI Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Garcia-Rey","sequence":"additional","affiliation":[{"name":"for the GEAS-SEMI Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Gonzalo","sequence":"additional","affiliation":[{"name":"for the GEAS-SEMI Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Diez-Gal\u00e1n","sequence":"additional","affiliation":[{"name":"for the GEAS-SEMI Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisa","family":"de la Rica-Escu\u00edn","sequence":"additional","affiliation":[{"name":"for the GEAS-SEMI Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Martinez-Lostao","sequence":"additional","affiliation":[{"name":"for the GEAS-SEMI Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adela","family":"Mar\u00edn Ballv\u00e9","sequence":"additional","affiliation":[{"name":"for the GEAS-SEMI Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Luisa","family":"Taboada-Mart\u00ednez","sequence":"additional","affiliation":[{"name":"for the GEAS-SEMI Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rub\u00e9n","family":"Pamp\u00edn-S\u00e1nchez","sequence":"additional","affiliation":[{"name":"for the GEAS-SEMI Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Helguera-Am\u00e9zua","sequence":"additional","affiliation":[{"name":"for the GEAS-SEMI Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Fern\u00e1ndez-Madera-Mart\u00ednez","sequence":"additional","affiliation":[{"name":"for the GEAS-SEMI Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estela","family":"Garc\u00eda-Coya","sequence":"additional","affiliation":[{"name":"for the GEAS-SEMI Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Mar\u00eda","family":"\u00c1lvarez-Suarez","sequence":"additional","affiliation":[{"name":"for the GEAS-SEMI Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngel","family":"Robles","sequence":"additional","affiliation":[{"name":"for the GEAS-SEMI Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Noblejas","sequence":"additional","affiliation":[{"name":"for the GEAS-SEMI Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Soto","sequence":"additional","affiliation":[{"name":"for the GEAS-SEMI Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Mart\u00ednez","sequence":"additional","affiliation":[{"name":"for the GEAS-SEMI Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Arnalich","sequence":"additional","affiliation":[{"name":"for the GEAS-SEMI Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coral","family":"Ar\u00e9valo","sequence":"additional","affiliation":[{"name":"for the GEAS-SEMI Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ang\u00e9lica\u00a0","family":"L\u00f3pez-Rodr\u00edguez","sequence":"additional","affiliation":[{"name":"for the GEAS-SEMI Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Cobeta","sequence":"additional","affiliation":[{"name":"for the GEAS-SEMI Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Hidalgo","sequence":"additional","affiliation":[{"name":"for the GEAS-SEMI Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Diz","sequence":"additional","affiliation":[{"name":"for the GEAS-SEMI Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"for the GEAS-SEMI Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Bara","sequence":"additional","affiliation":[{"name":"for the GEAS-SEMI Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Fabregate","sequence":"additional","affiliation":[{"name":"for the GEAS-SEMI Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Jim\u00e9nez","sequence":"additional","affiliation":[{"name":"for the GEAS-SEMI Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana","family":"Zhilina","sequence":"additional","affiliation":[{"name":"for the GEAS-SEMI Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Pellicer-Ari\u00f1o","sequence":"additional","affiliation":[{"name":"for the GEAS-SEMI Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Rodr\u00edguez -N\u00fa\u00f1ez","sequence":"additional","affiliation":[{"name":"for the GEAS-SEMI Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Ribot -Grabalosa","sequence":"additional","affiliation":[{"name":"for the GEAS-SEMI Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00edriam","family":"Costafreda-Mas","sequence":"additional","affiliation":[{"name":"for the GEAS-SEMI Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adri\u00e1n","family":"Tom\u00e9-P\u00e9rez","sequence":"additional","affiliation":[{"name":"for the GEAS-SEMI Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Hospital-Vidal","sequence":"additional","affiliation":[{"name":"for the GEAS-SEMI Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Ladino-V\u00e1zquez","sequence":"additional","affiliation":[{"name":"for the GEAS-SEMI Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alma","family":"Morancho-Ses\u00e9","sequence":"additional","affiliation":[{"name":"for the GEAS-SEMI Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adelaido","family":"Salazar-Rustarazo","sequence":"additional","affiliation":[{"name":"for the GEAS-SEMI Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Gabara-Xanc\u00f3","sequence":"additional","affiliation":[{"name":"for the GEAS-SEMI Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arturo","family":"Gonzalez -Quintela","sequence":"additional","affiliation":[{"name":"for the GEAS-SEMI Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernardo","family":"Sope\u00f1a","sequence":"additional","affiliation":[{"name":"for the GEAS-SEMI Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosario","family":"Alende -Sixto","sequence":"additional","affiliation":[{"name":"for the GEAS-SEMI Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Esteban","sequence":"additional","affiliation":[{"name":"for the GEAS-SEMI Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Rodriguez-Nu\u00f1ez","sequence":"additional","affiliation":[{"name":"for the GEAS-SEMI Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariadna Helena","family":"Andrade-Pi\u00f1a","sequence":"additional","affiliation":[{"name":"for the GEAS-SEMI Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria \u00c1ngeles","family":"Sanchidrian-Chapinal","sequence":"additional","affiliation":[{"name":"for the GEAS-SEMI Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Varela","sequence":"additional","affiliation":[{"name":"for the GEAS-SEMI Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Taboada","sequence":"additional","affiliation":[{"name":"for the GEAS-SEMI Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda","family":"Maure-Noia","sequence":"additional","affiliation":[{"name":"for the GEAS-SEMI Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"L\u00f3pez-Dom\u00ednguez","sequence":"additional","affiliation":[{"name":"for the GEAS-SEMI Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Filloy-Mato","sequence":"additional","affiliation":[{"name":"for the GEAS-SEMI Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Gimena-Reyes","sequence":"additional","affiliation":[{"name":"for the GEAS-SEMI Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisol","family":"Samart\u00edn-Ucha","sequence":"additional","affiliation":[{"name":"for the GEAS-SEMI Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caritina","family":"V\u00e1zquez-Tri\u00f1anes","sequence":"additional","affiliation":[{"name":"for the GEAS-SEMI Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Fern\u00e1ndez-Mart\u00edn","sequence":"additional","affiliation":[{"name":"for the GEAS-SEMI Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adolfo","family":"Paradela-Carreiro","sequence":"additional","affiliation":[{"name":"for the GEAS-SEMI Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Mar\u00eda","family":"Regueira-Arcay","sequence":"additional","affiliation":[{"name":"for the GEAS-SEMI Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Esteban-Marcos","sequence":"additional","affiliation":[{"name":"for the GEAS-SEMI Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Martin-Pena","sequence":"additional","affiliation":[{"name":"for the GEAS-SEMI Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Antonio","family":"Fern\u00e1ndez-Navarro","sequence":"additional","affiliation":[{"name":"for the GEAS-SEMI Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noelia","family":"Abdilla-Bonias","sequence":"additional","affiliation":[{"name":"for the GEAS-SEMI Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaume","family":"Mestre-Torres","sequence":"additional","affiliation":[{"name":"for the GEAS-SEMI Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana Rita","family":"Marques-Soares","sequence":"additional","affiliation":[{"name":"for the GEAS-SEMI Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep","family":"Pardos-Gea","sequence":"additional","affiliation":[{"name":"for the GEAS-SEMI Group"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2023,4,7]]},"reference":[{"key":"zoi230238r1","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.ajem.2022.01.028","article-title":"Clinical update on COVID-19 for the emergency clinician: presentation and evaluation.","volume":"54","author":"Long","year":"2022","journal-title":"Am J Emerg Med"},{"issue":"10332","key":"zoi230238r2","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1016\/S0140-6736(22)00462-7","article-title":"Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study.","volume":"399","author":"Nyberg","year":"2022","journal-title":"Lancet"},{"key":"zoi230238r3","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.ajem.2020.03.036","article-title":"Coronavirus disease (COVID-19): a primer for emergency physicians.","volume":"44","author":"Chavez","year":"2021","journal-title":"Am J Emerg Med"},{"issue":"7","key":"zoi230238r4","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102567","article-title":"Should we stimulate or suppress immune responses in COVID-19? cytokine and anti-cytokine interventions.","volume":"19","author":"Jamilloux","year":"2020","journal-title":"Autoimmun Rev"},{"issue":"10229","key":"zoi230238r5","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: consider cytokine storm syndromes and immunosuppression.","volume":"395","author":"Mehta","year":"2020","journal-title":"Lancet"},{"issue":"13","key":"zoi230238r6","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1001\/jama.2020.2648","article-title":"Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72?314 cases from the Chinese Center for Disease Control and Prevention.","volume":"323","author":"Wu","year":"2020","journal-title":"JAMA"},{"issue":"50","key":"zoi230238r7","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abd6832","article-title":"Natural killer cell immunotypes related to COVID-19 disease severity.","volume":"5","author":"Maucourant","year":"2020","journal-title":"Sci Immunol"},{"issue":"1","key":"zoi230238r8","doi-asserted-by":"publisher","first-page":"386","DOI":"10.7150\/ijbs.65911","article-title":"COVID-19: systemic pathology and its implications for therapy.","volume":"18","author":"Shen","year":"2022","journal-title":"Int J Biol Sci"},{"issue":"24","key":"zoi230238r9","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000006656","article-title":"Refractory adult-onset Still disease complicated by macrophage activation syndrome and acute myocarditis: a case report treated with high doses (8?mg\/kg\/d) of anakinra.","volume":"96","author":"Parisi","year":"2017","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"zoi230238r10","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1097\/CCM.0000000000001402","article-title":"Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: reanalysis of a prior phase III trial.","volume":"44","author":"Shakoory","year":"2016","journal-title":"Crit Care Med"},{"issue":"9","key":"zoi230238r11","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1177\/0885066617711386","article-title":"Interleukin 1 receptor antagonist anakinra, intravenous immunoglobulin, and corticosteroids in the management of critically ill adult patients with hemophagocytic lymphohistiocytosis.","volume":"34","author":"Wohlfarth","year":"2019","journal-title":"J Intensive Care Med"},{"key":"zoi230238r12","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.ijid.2020.11.149","article-title":"Anakinra in hospitalized patients with severe COVID-19 pneumonia requiring oxygen therapy: results of a prospective, open-label, interventional study.","volume":"103","author":"Balkhair","year":"2021","journal-title":"Int J Infect Dis"},{"issue":"2","key":"zoi230238r13","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.jaci.2020.11.006","article-title":"Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: an observational cohort study.","volume":"147","author":"Bozzi","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"32","key":"zoi230238r14","doi-asserted-by":"publisher","first-page":"18951","DOI":"10.1073\/pnas.2009017117","article-title":"Early IL-1 receptor blockade in severe inflammatory respiratory failure complicating COVID-19.","volume":"117","author":"Cauchois","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"zoi230238r15","doi-asserted-by":"publisher","first-page":"e253","DOI":"10.1016\/S2665-9913(21)00012-6","article-title":"Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study.","volume":"3","author":"Cavalli","year":"2021","journal-title":"Lancet Rheumatol"},{"issue":"7","key":"zoi230238r16","doi-asserted-by":"publisher","first-page":"e393","DOI":"10.1016\/S2665-9913(20)30164-8","article-title":"Anakinra for severe forms of COVID-19: a cohort study.","volume":"2","author":"Huet","year":"2020","journal-title":"Lancet Rheumatol"},{"issue":"1","key":"zoi230238r17","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1186\/s13054-020-03364-w","article-title":"Anakinra treatment in critically ill COVID-19 patients: a prospective cohort study.","volume":"24","author":"Kooistra","year":"2020","journal-title":"Crit Care"},{"key":"zoi230238r18","doi-asserted-by":"publisher","first-page":"10","DOI":"10.7554\/eLife.66125","article-title":"An open label trial of anakinra to prevent respiratory failure in COVID-19.","volume":"10","author":"Kyriazopoulou","year":"2021","journal-title":"Elife"},{"issue":"3","key":"zoi230238r19","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.chest.2020.09.275","article-title":"Comparative survival analysis of immunomodulatory therapy for coronavirus disease 2019 cytokine storm.","volume":"159","author":"Narain","year":"2021","journal-title":"Chest"},{"issue":"4","key":"zoi230238r20","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.jaci.2021.01.024","article-title":"Efficacy of early anti-inflammatory treatment with high doses of intravenous anakinra with or without glucocorticoids in patients with severe COVID-19 pneumonia.","volume":"147","author":"Pontali","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"zoi230238r21","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S2213-2600(20)30556-7","article-title":"Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial.","volume":"9","author":"CORIMUNO-19 Collaborative Group","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"10","key":"zoi230238r22","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1038\/s41591-021-01499-z","article-title":"Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial.","volume":"27","author":"Kyriazopoulou","year":"2021","journal-title":"Nat Med"},{"issue":"1","key":"zoi230238r23","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD015308","article-title":"Interleukin-1 blocking agents for treating COVID-19.","volume":"1","author":"Davidson","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"issue":"20","key":"zoi230238r24","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"2","key":"zoi230238r25","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1002\/art.v72.2","article-title":"Benefit of anakinra in treating pediatric secondary hemophagocytic lymphohistiocytosis.","volume":"72","author":"Eloseily","year":"2020","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"zoi230238r26","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1002\/acr2.v2.5","article-title":"Continuous intravenous anakinra infusion to calm the cytokine storm in macrophage activation syndrome.","volume":"2","author":"Monteagudo","year":"2020","journal-title":"ACR Open Rheumatol"},{"issue":"8","key":"zoi230238r27","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in hospitalized patients with Covid-19.","volume":"384","author":"Horby","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"zoi230238r28","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2022.100560","article-title":"Development and validation of SCOPE score: a clinical score to predict COVID-19 pneumonia progression to severe respiratory failure.","volume":"3","author":"Giamarellos-Bourboulis","year":"2022","journal-title":"Cell Rep Med"},{"issue":"19","key":"zoi230238r30","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of Covid-19: final report.","volume":"383","author":"Beigel","year":"2020","journal-title":"N Engl J Med"},{"issue":"10","key":"zoi230238r31","doi-asserted-by":"publisher","DOI":"10.12890\/2021_002821","article-title":"Delayed use of the recombinant human IL-1 receptor antagonist anakinra in five COVID-19 patients with pulmonary fibrosis and persistent hypoxaemia: a preliminary report.","volume":"8","author":"Nan","year":"2021","journal-title":"Eur J Case Rep Intern Med"},{"key":"zoi230238r29","unstructured":"COVID-NMA Initiative. A living mapping and living systematic review of Covid-19 trials. Accessed March 2, 2023. https:\/\/covid-nma.com\/"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2803480\/fanlo_2023_oi_230238_1680183095.67807.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,7]],"date-time":"2023-04-07T15:02:07Z","timestamp":1680879727000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2803480"}},"subtitle":["A Randomized Phase 2\/3 Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2023,4,7]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.7243","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,7]]}}}